NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Multi-Modal Cancer Therapies > Classification system uncovers new information about ovarian cancers

Classification system uncovers new information about ovarian cancers

18 January 2021 · Listed under Multi-Modal Cancer Therapies

An Oxford-based ovarian cancer specialist has published a paper outlining a new classification which categorises different subtypes of cells and determines which ones can lead to more severe cancer outcomes.

Prof-Ahmed Ahmed-(Image: Ovarian Cancer Action)

This approach, dubbed the ‘Oxford Classification of Carcinoma of the Ovary’ or ‘Oxford Classic’ for short, was developed by Professor Ahmed Ahmed, who is supported by the NIHR Oxford Biomedical Research Centre.

In 2020, using single cell RNA sequencing, Prof Ahmed’s team made a breakthrough by identifying new types of fallopian tube cells that are the cells of origin for the majority of ovarian cancers.

They showed that that the types of these newly-discovered non-cancer cells are ‘mirrored’ into different ovarian cancer subtypes. These subtypes correlated well with survival.

Discovering the new subtypes of cells has allowed the Oxford researchers to classify and categorise tumours based on their origin in the body, and determine which ones can lead to more severe cancer outcomes.

This Oxford Classic approach will provide much more accurate predictions for disease outcome in patients, as well as helping researchers to develop targeted therapies for each type of cancer

Prof Ahmed, of the Nuffield Department of Women’s and Reproductive Health and Director of the Ovarian Cancer Cell Laboratory at the Weatherall Institute of Molecular Medicine, has how published a paper in collaboration with Imperial College demonstrating the applications of the Oxford Classic approach, as well as shedding light on some previously unknown information about ovarian cancers.

Prof Ahmed said: “Our group is very excited that we were able to confirm the predictive role of the Oxford Classic. This work highlights that it is now important to identify new personalised therapies for the Oxford Classic-defined EMT-high ovarian cancer subtype.

“The finding that there is a strong connection with abundant M2 Macrophages already offers a good hint as to where we could find good treatment options for patients with this type.”

Read more via the Cancer Research UK Oxford Centre.

Read the fully study.

← Using AI to improve the quality of endoscopy videos
New clinical prediction tools for myeloma developed →

News

  • BRC study outlines researchers training needs and barriers 20 May 2022
  • Three new Blood and Transplant Research Units created in Oxford 18 May 2022
  • Oxford’s medical, health and life sciences research excellence recognised 12 May 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre